ResearcherUniversity of CopenhagenActive in the last 2 years

Lars Henning Engelholm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6616-1232; OpenAlex author ID A5052701102. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2025: 1 paper

Papers 1

Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models. Last author DOI 10.1126/sciadv.adq0513 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Virginia Metrangolo · 1 shared paper, 2025 · strength 0.24
- Paper Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic … DOI 10.1126/sciadv.adq0513 ↗
Matthew J. Flick · 1 shared paper, 2025 · strength 0.24
- Paper Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic … DOI 10.1126/sciadv.adq0513 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.